<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00023634</url>
  </required_header>
  <id_info>
    <org_study_id>S0114</org_study_id>
    <secondary_id>U10CA032102</secondary_id>
    <secondary_id>R01CA082661</secondary_id>
    <secondary_id>S0114</secondary_id>
    <secondary_id>UW-106</secondary_id>
    <nct_id>NCT00023634</nct_id>
  </id_info>
  <brief_title>S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer</brief_title>
  <official_title>An Early Phase Study of an EGFRvIII Peptide Based Vaccine in Patients With EGFRvIII Expressing Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill&#xD;
      cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying two different vaccines to treat patients who have&#xD;
      gastric, prostate, or ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the toxicity of EGFRvIII peptide vaccine with sargramostim (GM-CSF) or keyhole&#xD;
           limpet hemocyanin (KLH) as adjuvant in patients with EGFRvIII-expressing cancer.&#xD;
&#xD;
        -  Determine the preexisting antibody and T-cell responses to EGFRvIII in these patients.&#xD;
&#xD;
        -  Determine the antibody and T-cell responses to EGFRvIII peptide after immunization with&#xD;
           this vaccine with GM-CSF or KLH as adjuvant.&#xD;
&#xD;
      OUTLINE: Patients are assigned to one of two treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive a vaccine containing EGFRvIII peptide admixed with sargramostim&#xD;
           (GM-CSF) intradermally monthly.&#xD;
&#xD;
        -  Arm II: Patients receive a vaccine containing EGFRvIII peptide admixed with keyhole&#xD;
           limpet hemocyanin subcutaneously monthly.&#xD;
&#xD;
      Treatment in both arms continues for 6 months in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients (12 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of accrual&#xD;
  </why_stopped>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>toxicity</measure>
    <time_frame>during treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Brain Tumors</condition>
  <condition>Gastric Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>EGFR vaccine with GMCSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGFR antisense DNA 500 mcg peptide w/GMCSF monthly x 6 m</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EGFR vaccine with KLH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGFR antisense DNA 500 mcg peptide w/KLH monthly x 6 m</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KLH</intervention_name>
    <description>100 mcg w/EGFRvIII</description>
    <arm_group_label>EGFR vaccine with KLH</arm_group_label>
    <other_name>keyhole limpet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GMCSF</intervention_name>
    <description>arm 1: 100 mcg w/EGFRvIII</description>
    <arm_group_label>EGFR vaccine with GMCSF</arm_group_label>
    <other_name>sargramostim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of one the following:&#xD;
&#xD;
               -  Stage II-IV gastric cancer&#xD;
&#xD;
               -  Stage IIC-IV ovarian cancer in first complete remission&#xD;
&#xD;
                    -  CA 125 normal and stable*&#xD;
&#xD;
               -  Grade III anaplastic astrocytoma&#xD;
&#xD;
               -  Stage IV (M1) prostate adenocarcinoma&#xD;
&#xD;
                    -  No small cell variations&#xD;
&#xD;
                    -  No biochemical progression after definitive surgery, defined by the&#xD;
                       following:&#xD;
&#xD;
                         -  Prostate-specific antigen more than 0.4 ng/mL which remains elevated on&#xD;
                            2 additional measurements at least 2 weeks apart after prostatectomy&#xD;
&#xD;
                         -  Three consecutive rises in PSA, each at least 1 month apart after&#xD;
                            definitive radiotherapy&#xD;
&#xD;
                    -  Must be receiving androgen blockade&#xD;
&#xD;
                    -  PSA less than 5 ng/mL and stable*&#xD;
&#xD;
          -  Documented EGFRvIII expression in primary tumor&#xD;
&#xD;
          -  Must have received prior surgery and or chemoradiotherapy for disease (except prostate&#xD;
             cancer patients) NOTE: *Stable defined as no increase over 2 measurements at least 28&#xD;
             days apart with the last measurement within the past 28 days&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  80 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Zubrod 0&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  SGOT no greater than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
          -  No hepatitis&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other malignancy in the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated&#xD;
             stage I or II cancer in complete remission&#xD;
&#xD;
          -  No contraindication to receiving sargramostim (GM-CSF) or KLH-based vaccine products&#xD;
&#xD;
          -  No autoimmune disease&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 month since prior cytotoxic chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 month since prior treatment dose corticosteroids&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from all prior therapies&#xD;
&#xD;
          -  No concurrent enrollment on other phase I studies&#xD;
&#xD;
          -  No other concurrent immune modulators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert B. Montgomery, MD</last_name>
    <role>Study Chair</role>
    <affiliation>VA Puget Sound Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bay Regional Medical Center</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Regional Cancer Center at Mercy Hospital</name>
      <address>
        <city>Port Huron</city>
        <state>Michigan</state>
        <zip>48060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital Community Cancer Center</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympic Hematology and Oncology</name>
      <address>
        <city>Bremerton</city>
        <state>Washington</state>
        <zip>98310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skagit Valley Hospital Cancer Care Center</name>
      <address>
        <city>Mt. Vernon</city>
        <state>Washington</state>
        <zip>98273</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Group Health Central Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute at Swedish Medical Center - First Hill Campus</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cancer Center at University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-6043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Puget Oncology at United General Hospital</name>
      <address>
        <city>Sedro-Wooley</city>
        <state>Washington</state>
        <zip>98284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest - Spokane South</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Clinic</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>September 13, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II gastric cancer</keyword>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

